Head-to-head
MEDVi vs LillyDirect (Zepbound)
Compared on tirzepatide across the eight dimensions this database records. They differ on 6 of those eight. MEDVi is cheaper on all-in tirzepatide at 10 mg/week, though on a flat-versus-tiered matchup the cheaper program can change further up the dose ladder.
The short answer
MEDVi is $399 a month all-in for tirzepatide; LillyDirect (Zepbound) is $449. Over twelve months that is $4,788 against $5,388. Value Scores are 57.4 and 46.3 out of 100.
Tirzepatide
Plan pages: MEDVi plans · LillyDirect (Zepbound) plans
At 10 mg/week, MEDVi is $399 a month all-in and LillyDirect (Zepbound) is $449 — $50 apart, or $600 across a year. Over twelve months the totals are $4,788 (billed monthly) and $5,388 (billed monthly).
MEDVi charges a flat $399 per month for tirzepatide at every dose from 2.5 to 15 mg per week, so titrating upward does not change what you pay.
LillyDirect (Zepbound) prices tirzepatide by dose: $299 per month at 2.5 mg rising to $449 at 7.5 mg, a difference of $150 a month between the bottom and top of the ladder.
| Dose | MEDVi | Rank | LillyDirect (Zepbound) | Rank | Cheaper |
|---|---|---|---|---|---|
| 2.5 mg | $399 | 27/31 | $299 | 18/31 | LillyDirect (Zepbound) by $100 |
| 5 mg | $399 | 15/17 | $399 | 14/17 | level |
| 7.5 mg | $399 | 14/17 | $449 | 16/17 | MEDVi by $50 |
| 10 mg | $399 | 21/27 | $449 | 24/27 | MEDVi by $50 |
| 12.5 mg | $399 | 14/17 | $449 | 16/17 | MEDVi by $50 |
| 15 mg | $399 | 14/17 | $449 | 16/17 | MEDVi by $50 |
The lead changes with the dose. Between 2.5 mg and 5 mg it passes to MEDVi. Pick on the dose you expect to settle at, not the headline.
Across the 27 programs this database can rank on tirzepatide, MEDVi sits 21 of 27 on all-in monthly cost and LillyDirect (Zepbound) sits 23. There is 1 other program priced between them. The field median is $339 and the floor is $169, so both sit above the median. MEDVi is $230 above the cheapest tirzepatide program on record. LillyDirect (Zepbound) is $280 above the cheapest tirzepatide program on record.
LillyDirect (Zepbound), the lowest FDA-approved tirzepatide channel here, is $449 a month — MEDVi undercuts it by $50, LillyDirect (Zepbound) by $0. Compounded products are not FDA approved; insurance can reverse that comparison.
| Plan term | MEDVi | LillyDirect (Zepbound) | Cheaper |
|---|---|---|---|
| Month to month | $399 | $449 | MEDVi by $50 |
| Settled dose | MEDVi | LillyDirect (Zepbound) | Difference |
|---|---|---|---|
| 2.5 mg | $4,788 | $3,588 | $1,200 apart |
| 5 mg | $4,788 | $4,788 | $0 apart |
| 7.5 mg | $4,788 | $5,388 | $600 apart |
| 10 mg | $4,788 | $5,388 | $600 apart |
| 12.5 mg | $4,788 | $5,388 | $600 apart |
| 15 mg | $4,788 | $5,388 | $600 apart |
MEDVi publishes no rate for 3-month term, 6-month term, 12-month term; LillyDirect (Zepbound) publishes none for 3-month term, 6-month term, 12-month term. An unpublished term is not necessarily unavailable — it is unpriced in public, which you can only resolve by asking.
A titration year is not twelve months at the maintenance price. Stepping up roughly four weeks per dose before settling at 10 mg/week, the first twelve months work out to $4,788 on MEDVi and $5,188 on LillyDirect (Zepbound) — $400 apart, and a different gap from the $600 you would get by multiplying the monthly difference by twelve. The ramp is cheaper than the settled rate on whichever program prices by dose, which is why a first-year quote and a steady-state quote are not the same number.
Value Scores are 57.4 for MEDVi and 46.3 for LillyDirect (Zepbound), against a tirzepatide category floor of $169. MEDVi leads by 11.1 points, and the margin comes from structure rather than price alone.
| Program | Price /70 | Evidence /15 | Dose /10 | Membership /5 | Total /100 |
|---|---|---|---|---|---|
| MEDVi | 29.6 | 12.8 | 10 | 5 | 57.4 |
| LillyDirect (Zepbound) | 26.4 | 15.0 | 0 | 5 | 46.3 |
Where the two programs differ
All-in monthly
MEDVi is cheaper month to month — $399 against $449, a gap of $50 every month, or $600 across a year if both rates hold.
Cancellation terms
Cancellation differs: MEDVi states Cancel before renewal, while LillyDirect (Zepbound) states No subscription lock. Read this next to the twelve-month figures — a prepaid discount and a restrictive refund policy are the same decision.
Commitment
MEDVi asks for Month-to-month; LillyDirect (Zepbound) asks for None; Journey Program pricing requires refill within 45 days on 7.5 mg+. This is the dimension most likely to change which program is actually cheaper for you, because the lowest rates on both sides are usually attached to the longest terms.
Dose policy
MEDVi charges one price at every dose; LillyDirect (Zepbound) prices by dose. That difference usually matters more than the headline gap, because the tiered program's advertised figure describes the dose you start on, not the dose you settle at.
Evidence status
The two prices are not equally well evidenced. MEDVi's figure is provider-stated and LillyDirect (Zepbound)'s is verified. LillyDirect (Zepbound) rests on the stronger of the two, and the Value Score below reflects that — evidence quality is worth fifteen points and is not a tiebreaker we apply after the fact.
Twelve-month cost
Over twelve months the totals are $4,788 for MEDVi and $5,388 for LillyDirect (Zepbound). MEDVi is lower by $600 — a figure worth checking against the cancellation terms below, because a prepaid year is only cheaper if you stay on it.
Membership fee
Neither charges a separate membership fee.
Shipping
Shipping is handled the same way by both — included in the quoted price.
What each record says
MEDVi Official site
MEDVi advertises a $179 semaglutide start that tiers to $299 at maintenance; tirzepatide is $399 flat.
It does not publicly name its compounding pharmacy; the record shows Partner pharmacies, so who actually makes the medication cannot be independently verified; commitment terms are Month-to-month; cancellation is Cancel before renewal; availability is stated as Most US states.
Evidence: provider-stated — taken from the provider's own published pages; checkout capture pending, captured . Source — medvi.com pricing capture 2026-08-05
Watch: Start-vs-maintenance spread on semaglutide; compare on maintenance.
LillyDirect (Zepbound) Official site
The manufacturer's own cash channel for FDA-approved Zepbound single-dose vials: $299/month at 2.5 mg, $399 at 5 mg, and $449 for every dose from 7.5 to 15 mg through the Self Pay Journey Program — provided each refill lands within 45 days of the last, otherwise that refill reverts to $599–$1,049 by dose. This is the cheapest FDA-approved tirzepatide in the country and the benchmark every compounded price should be judged against.
It names its compounding pharmacy — Eli Lilly self-pay pharmacy (GiftHealth), recorded as Manufacturer direct — which can be checked against state board licensing and FDA inspection records before you order; commitment terms are None; Journey Program pricing requires refill within 45 days on 7.5 mg+; cancellation is No subscription lock; availability is stated as 50 states.
Evidence: verified — captured at checkout by our desk on the stated date, captured . Source — Lilly investor announcement Dec 1, 2025 + LillyDirect program pages; corroborated by drugs.com pricing review updated Jun 12, 2026
Watch: The 45-day refill window is the whole game: one late refill at 10 mg costs $699 instead of $449.
Which molecules each one carries
MEDVi carries tirzepatide at $399 a month and semaglutide at $299 a month.
LillyDirect (Zepbound) carries tirzepatide at $449 a month; does not offer semaglutide.
Comparable only on tirzepatide: they do not both publish a rankable semaglutide price. Switching molecule mid-treatment would mean changing provider.
What neither record tells you
MEDVi does not publish
- no published twelve-month tirzepatide rate
- no named compounding pharmacy
- no state-by-state availability list — it says Most US states
LillyDirect (Zepbound) does not publish
- no published twelve-month tirzepatide rate
Ask MEDVi and LillyDirect (Zepbound) for each of those in writing before enrolling. A gap is not evidence of a problem; it does mean nothing can be checked against it.
What would change this answer
Neither program publishes a promotional rate with an end date, a prepaid term, or a price we have flagged for re-verification, so the comparison above is as stable as this dataset gets.
Which one suits which reader
On the lowest standing monthly rate for tirzepatide, MEDVi Official site wins this matchup. If you expect to titrate to the top of the ladder, medvi's flat pricing is worth more than the headline gap suggests; and if you would rather trust a better-evidenced number, lillydirect (zepbound)'s price rests on stronger provenance.
Both figures should be checked at the provider's own checkout before you pay. MEDVi's tirzepatide price is provider-stated as of 2026-08-05; LillyDirect (Zepbound)'s is verified as of 2026-08-11.
Questions
Is MEDVi or LillyDirect (Zepbound) cheaper for tirzepatide?
MEDVi is cheaper on all-in monthly cost at 10 mg/week: $399 against $449, a difference of $50 a month. All-in means the medication plus every mandatory recurring fee.
What is the twelve-month cost of MEDVi versus LillyDirect (Zepbound)?
MEDVi works out to $4,788 across twelve months and LillyDirect (Zepbound) to $5,388, on the plan terms each publishes.
Does MEDVi or LillyDirect (Zepbound) raise the price as the dose goes up?
MEDVi: no, it charges one flat rate at every dose. LillyDirect (Zepbound): yes, it prices by dose. Where one program is flat and the other is tiered, the cheaper of the two can change as you titrate upward.
How many ways do MEDVi and LillyDirect (Zepbound) differ?
6 of the eight dimensions this site records: all-in monthly, twelve-month cost, dose policy, membership, shipping, commitment, cancellation terms and evidence status.
Which of MEDVi and LillyDirect (Zepbound) names its pharmacy?
LillyDirect (Zepbound) does — Eli Lilly self-pay pharmacy (GiftHealth). MEDVi does not, recording only Partner pharmacies, so who makes its medication cannot be independently verified.
How well evidenced are the MEDVi and LillyDirect (Zepbound) prices?
MEDVi's tirzepatide figure is provider-stated — taken from the provider's own published pages; checkout capture pending — captured 2026-08-05. LillyDirect (Zepbound)'s is verified, captured 2026-08-11. Evidence status is worth fifteen points in the Value Score, so it is priced in rather than mentioned as an aside.
Official sources: MEDVi official site · LillyDirect (Zepbound) official site. Compounded tirzepatide and semaglutide are not FDA-approved products.